Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Effective date: January 8, 2025

PMcardio for Organizations Privacy Notice

for EEA / UK data subjects

This privacy notice outlines how We collect and process personal data as part of your use of the PM’s services and subscription services, including the associated PM mobile application, PM web platform and PM service account utilizing API or other services as agreed between PM and the Customer all under the product name PMcardio for Organisations (the “Services”) and provides further information relating to compliance with Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation) (the “GDPR”). This privacy notice applies to you if you are located in the European Economic Area or the United Kingdom.

Please see also the General Privacy Policy which outlines the general data protection practices and further uses of personal data by PM available here. The terms relating to the delivery and the use of the respective Services are outlined in the End user license agreement concluded between PM and Users for the purposes of provision of the Services (the “EULA“) available here, and, if applicable, the Master Service Agreement concluded between PM and the Customer for the purposes of provision of the Services including the applicable data processing addendum (the “Customer Agreement”).

Capitalised terms have the meaning defined in the General Privacy Policy, unless this Privacy Notice provides otherwise.

  1. Responsibility
    1. We, POWERFUL MEDICAL s. r. o., with registered seat at Karadžičova 8/A Bratislava – mestská časť Ružinov 821 08, the Slovak Republic, Company lD No.: 50 948 431, registered with the Commercial Register of the Municipal Court Bratislava III, Section: Sro; Insert No.: 184319/B (“PM”, “We” or “Us”) in general process personal data on behalf of the Customer in order to provide to the Customer the Services. In this regard, We act as a data processor and the Customer acts as data controller. Please see section 2.2(a) of this Privacy Notice for further detail.
    2. There are additional activities, where We are the data controller. In particular, the use of personal data for administration of the Application, its use and further research. Please see section 2.2(b) to (d) of this Privacy Notice for further detail.
  2. Terms of Processing of Personal Data
    1. How Do We Collect Data
      • We develop and operate the Services. The Services are base on an AI-powered assistant, which digitizes ECG recordings, provides comprehensive analyses, reports and recommendations to the User. The Services and access to the Services is managed either by you personally or by the Customer.
      • Within the Services the User scans ECG recordings of individuals selected by the User (patients) uploads the image to our severs, where our AI algorithms digitize, analyze, and interpret the ECG recording for further analysis. Based on the ECG analysis, disease-specific patient history questions may be generated. Upon answering the User may be provided with a patient management recommendation.
      • More details about the functionality can be found here.
    2. Processing Particulars. We process personal data for the following purposes:
      • Operation of the Services – ECG digitization / ECG interpretation consisting of segmentation, analysis and diagnosis; patient management recommendation).
        • Roles: In relation to this purpose, PM acts as a processor and the Customer acts as a controller. As such, the Customer is accountable for ensuring the provision of appropriate information to the underlying data subject and evidencing the right legal basis (e.g. consent or legal obligation to process personal data).
        • Legal basis: We process personal data on the basis of a data processing agreement concluded between Us and the Customer under Article 28 of the GDPR.
        • Data subjects: Such individuals as the Customer determines – User´s patients and Users.
        • Categories of data: Name, surname and contact details of Users, as well as data provided by the User relating to patients, in particular ECG image, sex, age, patient’s personal number (optional), and futher data required to determine patient management recommendations.
        • Retention period: Personal data will be retained in line with Customer’s instructions as the data controller. Deletion will be undertaken upon request by the Customer as the data controller.
      • Research to further improve the existing technologies – using provided ECG and related health data to improve the used technologies. All of the used data is de-identified and does not allow for identification of the patent.
        • Roles: PM acts as a controller.
        • Legal basis: Legitimate interest of the controller under Article 6(1)(f) and Article 9(2)(j) of the GDPR consisting in research of artificial intelligence. The processing is necessary for further development of the Application, its algorithm and software.
        • Data subjects: Individuals whose data has been uploaded by the User.
        • Categories of data: de-identified data of patients (data which does not allow an identification of the underlying individual) such as ECG image, sex, age, and further data required to determine patient management recommendations.
        • Retention period: Data is kept in de-identified form for such time as needed to achieve the purpose.
      • Administration of the Services – setting up User account, verifying the status as healthcare professional, overall system administration, compliance with regulatory requirements, defense against legal claims.
        • Roles: PM acts as a controller.
        • Legal basis: The processing is necessary for the performance of a contract to which the data subject is a party under Article 6(1)(b) of the GDPR, or processing is necessary for the pupose of legitimate interest under Article 6(1)(f) of the GDPR of the controller consisting in performance of contractual obligations, regulatory requirements and defense against legal claims. The applicable contract is the Customer Agreement concluded between Us and the Customer or the EULA.
        • Data subjects: The Customer and the User.
        • Categories of data: identification, contact details, workplace, occupation, profile picture, billing and transactional information.
        • Retention period: Data is kept until (i) Customer’s account in the Services is deleted; (ii) mandatory retention periods are satisfied (e. g. accounting); (iii) in case of other regulatory, legal requirements or litigation, kept until resolution of such requirements or litigation.
      • Medical device vigilance – Protecting and improving safeguards for patients, Users and others by preventing the likelihood of recurrence of incidents.
        • Roles: PM acts as a controller.
        • Legal basis: In accordance with Article 6(1)I of the GDPR, processing is necessary for compliance with a legal obligations (EU MDR 2017/745) to which PM is a subject.
        • Data subjects: Users, patients.
        • Categories of data: data of patients such as ECG image, sex, age, and futher data required to determine patient management recommendations; name, surname and occupation of Users.
        • Retention period: Data is retained during period stipulated by law, which is 10 years.
    3. Transfer to Third Countries
      • We store and process personal data within the European Economic Area (the “EEA”) or within countries recognized by the European Commission as providing adequate level of protection of personal data. We may, however, transfer personal data to countries outside the EEA in the following circumstances:
        • If the User resides, is based or operates the Application from a country outside of the EEA, the Personal Data from such use will be transferred to the EEA and back to the User;
        • In the limited circumstances where We use subprocessors who are located outside of the EEA; and
        • If We share personal data to other recipients strictly as necessary and in accordance with the Customer Agreement, EULA or the Privacy Notice.
      • Any transfer of personal data outside of the EEA is undertaken in compliance with the GDPR, in particular Chapter V of the GDPR and subject to the conclusion of Standard Contractual Clauses.
      • If you reside, are based or operate the Services from a country outside of the EEA, the Personal Data from such use will be transferred to the EEA.
    4. Recipients
      • We will not provide personal data to any third party other than (i) as necessary to perform activities outlined in the Customer Agreement and EULA, including our suppliers acting as subprocessors, who provide services to us, such as authentication, customer support; (ii) in accordance with the documented instructions of the Customer; (iii) within entities affiliated to Us by common control, management or ownership, (iv) as part of a merger, acquisition, investment by a third party or change of corporate structure of PM, or (v) as required to comply with the GDPR or other laws to which We are subject, in which case We shall (to the extent permitted by law) inform the Customer of that legal requirement before processing personal data.
    5. No Automated Decision-Making System, Profiling
      • The Services accesses algorithms in the backend, which then process and evaluate the ECG scan and other relevant data. Although this process is automated and We will provide the User with a resulting analysis of the data, no decision made by the automated decision-making system will have a legal impact on the data subject. Any and all decisions about or related to the data subject must be made by the User personally.
    6. Obligation to Provide Personal Data
      • Provision of any personal data is not an obligation and the data subject may freely refuse. However, failure to provide personal data would result in the impossibility to use the Application and benefit from it.
    7. Retention
      • The Company will retain data for as long as identified in section 2.2 “Processing Particulars”. After such time, or where relevant upon request, we will delete the relevant data without undue delay. Please note that although the secure and complete erasure from our back-ups may not be immediate, we will ensure that it is done as soon as technically feasible.
  3. Rights of Data Subjects
    1. As a data subject, you have a number of rights listed below. Please note the following important information:
      • Where We act as a processor (Section 2.2(a) above), any request shall be addressed to the Customer and/or User – as a controller, they are responsible to respond to any requests. We will provide our assistance to ensure your rights are fulfilled.
      • For any de-identified information (Section 2.2(b) above), We will not hold any directly identifiable data and it will be technically impossible to link the data to any individual. We may therefore not be in a position to identify you as a data subject about whom We would hold personal data.
    2. Data subjects have the following rights (subject to the rules contained in the GDPR and other applicable legislation):
      • Right to access: Data subjects have the right to request a copy of their personal data.
      • Right to rectification: Data subjects have the right to request to correct any inaccurate information.
      • Right to erasure: Data subjects have the right to request erasure of their personal data, under certain conditions.
      • Right to restrict processing: Data subjects have the right to request restriction of processing of their personal data, under certain conditions.
      • Right to object to processing: Data subjects have the right to object to processing of their personal data, under certain conditions. This applies in particular for processing under Section 2.2(b) and 2.2(c).
      • Right to portability: Data subjects have the right to request transfer of their personal data to another organization, or directly to them, under certain conditions.
      • Right to file a complaint with the relevant authority: Data subjects have the right to file a complaint with the Office for Personal Data Protection of the Slovak Republic, Hraničná 12, 820 07 Bratislava, Slovak Republic, statny.dozor@pdp.gov.sk; or, for data subjects located in the United Kingdom, with the Information Commissioner’s Office of the United Kingdom.
    3. In order to exercise their rights, data subjects can contact our Data Protection Officer at dpo@powerfulmedical.com.

All Supported ECG Findings

Rhythms
Sinus bradycardia • Sinus rhythm • Sinus tachycardia • Paced rhythm • Atrial fibrillation
Atrial fibrillation with rapid ventricular response • Atrial fibrillation with slow ventricular response • Atrial flutter • Atrial flutter with rapid ventricular response • Atrial flutter with slow ventricular response • Supraventricular tachycardia • Suspected junctional rhythm • Suspected junctional bradycardia • Suspected accelerated junctional rhythm • Wide QRS rhythm • Idioventricular rhythm • Wide QRS tachycardia

Myocardial Infarctions
  • STEMI
  • STEMI
    Equivalent
Detects occlusive myocardial infarctions (OMIs) even without ST elevation (i.e. posterior STEMI, hyperacute T-waves, etc.). Negative for STEMI mimics (i.e. early repolarization, LVH, etc.)
  • High-Risk NSTEMI
    Represents a type 1 myocardial infarction caused by a transiently recanalized coronary occlusion—classically seen in patterns such as Wellens type A or B due to subtotal LAD obstruction, but possible in any infarct-related territory.
  • Culprit Detection
    AI-predicted likelihood scores for LAD, LCx, and RCA with 3D heart visualization highlighting the predicted culprit artery.

Conduction Abnormalities (Heart Blocks
1st degree AV block • 2nd degree AV block, type Wenckebach • Higher degree AV block • Complete right bundle branch block • Incomplete right bundle branch block • Complete left bundle branch block • Incomplete left bundle branch block • Nonspecific intraventricular conduction delay • Left anterior fascicular block • Left posterior fascicular block • Bifascicular block (RBBB + LAFB) • Bifascicular block (RBBB + LPFB) • Trifascicular block (RBBB + LAFB + AVBLOCK1) • Trifascicular block (RBBB + LPFB + AVBLOCK1)

LVEF
Reduced LVEF (≤40%) • Mildly reduced LVEF (41 – 49%) • No signs of reduced LVEF (≥50%)

Axis
Left cardiac axis deviation • Right cardiac axis deviation • Extreme cardiac axis deviation • Normal axis

Measurements
Heart rate • P wave • PR interval • QRS duration • QT interval • Corrected QT interval (Framingham formula) • RR interval • PP interval • ST elevations

Other Supported Diagnoses
Suspected long QT syndrome • Suspected short QT syndrome • Suspected atrial enlargement • Suspected ventricular hypertrophy • Premature complexes

Dr. Tom De Potter, MD

Cardiologist at the Cardiac Center Aalst

Cardiologist specializing in Pacemaker Device Therapy and Electrophysiology. Leads the electrophysiology unit at the Heart Center in Aalst, holds an executive board position at the European Heart Academy, and serves as EHRA scientific program committee co-chair.

Dr. Martin Penicka, MD, PhD

Cardiologist at the Cardiac Center Aalst

Cardiologist at the Cardiac Center Aalst since 2009, specializing in non-invasive imaging and valvular disease. Fellow of the European Society of Cardiology (FESC) and the European Association of Cardiovascular Imaging (FEACVI).

Dr. Ward Heggermont, MD, PhD

Co-director at the Cardiovascular Center

Co-director at the Cardiovascular Center of Aalst Hospital, specializing in heart failure. Research focus at the intersection of cardiology, virology, and metabolism.

Prof. Dr. Robert Hatala, PhD

Co-founder and Chief Scientist

Head of the Arrhythmia and Pacing department at the National Institute of Cardiovascular Diseases in Slovakia. More than 150 publications and 10,000 citations. Contributor to ESC clinical practice guidelines and executive editor of the European Heart Journal since 2020.

Arieh Levy

Head of PMcardio for Individuals

Arieh leads the PMcardio for Individuals product at Powerful Medical, guiding its development as a clinical tool for emergency physicians, cardiologists, and primary care physicians. He holds a First Class MEng in Biomedical Engineering from Imperial College London, where he specialised in AI for cardiology, building physics-informed neural networks to model atrial electrical properties, giving him a background that bridges the clinical and technical demands of building a certified AI medical device used at the bedside every day.

Dr. Dave Pearson, MD​

Business Advisor

Academic emergency medicine physician, entrepreneur, investor, and researcher with nearly two decades at Atrium Health, one of US largest health systems. Brings expertise at the intersection of clinical care, healthcare innovation, and strategic leadership.

Prof. Stephen W. Smith, MD

Professor of Emergency Medicine

Faculty physician in Emergency Medicine at Hennepin County Medical Center and Professor of Emergency Medicine at the University of Minnesota. Co-inventor of the OMI paradigm and editor of Dr. Smith’s ECG Blog, the most-visited US-based ECG interpretation blog.

Prof. Emanuele Barbato, MD, PhD

President of EAPCI

Interventional cardiologist specializing in coronary artery disease and coronary physiology. Acting president of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and contributor to the clinical practice guidelines for STEMI care.

Scott Sharkey, MD

Chief Medical Officer

Chief Medical Officer of the Minneapolis Heart Institute Foundation and practicing cardiologist at Allina Health Minneapolis Heart Institute. Co-founder of the STEMI Midwest consortium and Takotsubo cardiomyopathy research program and a widely published clinical investigator in STEMI care.

Prof. Dr. Leor Perl, MD

Director of Cardiac Catheterization Institute

Director of Complex Cardiac Interventions and Chief Innovation Officer at Rabin Medical Center. Graduate of the Stanford Biodesign Program.

Suzanne J. Baron, MD, MSc

Director of Interventional Cardiology Research

Director of Interventional Cardiology Research at Massachusetts General Hospital. Holds a Master’s degree in health economics from Harvard School of Public Health. Expert in cardiovascular device impact on healthcare costs and patient-reported outcomes.

Prof. Marco Valgimigli, MD

Deputy Chief Cardiocentro Ticino Institute

Head of Cardiology at Cardiocentro Ticino and Principal Investigator of the TITAN-OMI randomized controlled trial. His research has shaped both European and US clinical practice guidelines on coronary stents, antithrombotic therapy, and vascular access.

Timothy D. Henry, MD

Medical Director of The Carl and Edyth Lindner Center

Leading expert in interventional cardiology and STEMI treatment. Co-founder and principal investigator of the Midwest STEMI Consortium, a registry of more than 20,000 consecutive STEMI activations. Presenting author for the TCT 2025 Late-Breaking Clinical Science on Queen of Hearts.

Matus Horvath

Head of People

Matus leads hiring strategy and culture at Powerful Medical. He previously ran the People Team at Slido, the Slovak SaaS startup later acquired by Cisco — an experience that informs how he builds a high-performing, values-driven team through rapid scaling.

Dr. Timea Kisova, MD

Clinical Research Lead

Timea leads Powerful Medical’s global external validation studies, including the multi-country AI ECG TIMI Study. With a background in biomedical sciences and a medical degree from Barts and The London School of Medicine and Dentistry, she brings the clinical discipline required to generate the prospective, real-world evidence behind every PMcardio module.

Dr. Anthony Demolder, MD, PhD

HF Pathway Lead

Research physician with a PhD on arrhythmias in heritable thoracic aortic disease. He has led international studies at the intersection of cardiology and AI — including earlier work on atrial fibrillation at AZ Sint-Jan Brugge — and now drives Powerful Medical’s heart failure pathway and LVsense™ AI model development.

Dr. Pendell Meyers, MD

ACS Pathway Lead

Emergency medicine physician, prolific educator, and Co-Editor of Dr. Smith’s ECG Blog. He is one of the leading voices behind the Occlusion Myocardial Infarction (OMI) paradigm, the clinical framework that reshaped how heart attacks are identified from the ECG — and which sits at the core of the Queen of Hearts™ model.

Adam Dej

Head of PMcardio for Organizations Engineering

Adam leads engineering for PMcardio for Organizations at Powerful Medical, driving platform architecture, backend systems, and infrastructure behind one of the company’s key growth products. He began programming at 13, entered professional IT at 17, and studied computer security at Comenius University’s Faculty of Mathematics, Physics and Informatics. Known for technical depth across distributed systems, infrastructure, and security, he builds scalable and resilient software with a sharp focus on customer impact. He also champions responsible use of AI and LLMs as force multipliers for modern engineering teams.

Gabriela Rovder Sklencarova

Head of Infrastructure

Gabriela designs the scalable, secure, distributed systems that keep PMcardio running around the clock for clinicians worldwide. She joined from Google, where she was a senior software engineer building core libraries that kept Google’s services resilient against billions of requests, and holds a BA and MA in Computer Science from the University of Cambridge.

Arezou Azar

US and Global Regulatory

Arezou leads Powerful Medical’s global regulatory strategy across the FDA, EU MDR, and international frameworks. She has been part of nearly every major breakthrough in AI cardiology and is an expert in US and global regulatory strategy, SaMD/digital health launches, with experience at Eko Health, Verily, AliveCor, Cardiologs, and Apple. She specializes in regulatory strategy in high-paced global organizations.

Adam Rafajdus

Head of AI

Adam grew into the Head of AI role from MLOps Engineer over six years at Powerful Medical, bringing deep expertise in deep learning and production-grade system deployment. He leads the team behind the Queen of Hearts™ AI ECG models and was awarded Best Poster at ISCE 2025 for the company’s ECG digitization pipeline.

Mike Wall

VP of Sales

Mike brings more than twenty years at UnitedHealth Group to the table, where he served health plans, employer groups, and public-sector entities as a consultative healthcare sales executive. He combines market intelligence, clinical insight, and financial acumen — the three ingredients needed to bring AI-powered diagnostics into US health systems at scale.

Amani Farid

Head of Strategic Partnerships

Amani leads partnership strategy with a hands-on approach to integration, unlocking long-term value through collaboration and scale. A University of Chicago Law School-trained attorney and former M&A and capital markets associate at two top international law firms, she brings the rare combination of legal precision and commercial execution refined across nearly a decade at Stryker and as VP of Corporate Development at RapidAI — spanning medtech, digital health, and AI-driven diagnostics.

Michal Martonak

Commercial Lead

A mathematician by training, Michal leads commercial strategy, go-to-market, and strategic partnerships with healthcare providers and clinical institutions worldwide. He previously built Powerful Medical’s data and clinical partnerships function, acquiring the large-scale clinical datasets that underpin the company’s certified AI models.

Dr. Jozef Bartunek, MD, PhD

Co-founder and VP Clinical Strategy

Interventional cardiologist and Co-director of the Cardiovascular Center in Aalst, Belgium — one of the world’s leading heart centers. A Fogarty International NIH Fellow at Harvard Medical School and visiting Professor of Medicine at Catholic University Leuven, he has authored more than 240 peer-reviewed publications in heart failure and structural heart disease, and anchors Powerful Medical’s clinical and research strategy.

Simon Rovder

Co-founder and CTO

Simon began his engineering career at Microsoft and holds a Master’s degree in Informatics from the University of Edinburgh. He built and scaled Powerful Medical’s technology organization from the ground up to a team of 20+ engineers, leading the architecture of a CE-certified Class IIb medical device now deployed in hospitals across Europe.

Viktor Jurasek

Co-founder and CPO

Viktor was modding computer games before his teens and has spent the last decade shipping digital products across advertising, finance, and healthcare. As co-founder and CPO, he has led PMcardio’s product and design since the first prototype, setting the bar for how a clinical-grade tool should feel in a physician’s hands — fast, clear, and trustworthy at the point of care.

Felix Bauer

Co-founder and COO

Felix was part of the Hyperloop team that repeatedly competed and won in Elon Musk’s SpaceX Hyperloop Pod Competition. He holds a degree from the Technical University of Munich and brings a rare combination of engineering rigor, regulatory discipline, and operational excellence to the company, spearheading operations, compliance, regulatory, quality management, and global market access since day one.

Dr. Robert Herman, MD, PhD

Co-founder and Chief Medical Officer

Robert is a physician-scientist who served on the Research, Digital and Innovation Committee of the European Society of Cardiology. He bridges medicine and AI, connecting clinicians, researchers, regulators, and trial leaders to translate algorithms into clinical practice. He founded multiple AI ECG models, leads international clinical trials validating them, is a recipient of the Journal of the American College of Cardiology Spencer King Award, and was named to Forbes 30 Under 30 Europe 2024.

Martin Herman

Co-founder and CEO

Martin started coding at 14 and moved to Silicon Valley at 18, founding several companies including a US-based startup before returning to Europe with his brother Robert to build Powerful Medical. He comes from a family of doctors, which shaped his conviction that AI belongs wherever it can genuinely save lives. Forbes 30 Under 30 (Europe 2024).

Heart Attacks are #1 cause of death world-wide and killing about 12 milions people a year.

Clinical Definition of Problem

Contrary to popular belief, a heart attacks isn’t a blockage inside of the heart. A heart attack is a blockage of the coronary arteries supplying the heart muscle with oxygenated blood.

So let’s assume you get a blood clot here — it blocks the blood flow downstream, meaning the heart muscle doesn’t get oxygenated blood and heart tissue downstream starts to die.

Clinical Solution​

The way to fix it is relatively simple – doctors put in a stent that opens up the artery and renews blood flow. The latest clinical practice guidelines recommend that this “stenting” happens within 90 minutes from symptom onset.

If you don’t, even if you put in the stent in later, the heart tissue downstream has already been permanently damaged, which reduces the heart’s ability to pump blood. This is the leading cause of heart failure and increases 1-year mortality by two-fold.

Time is muscle.

You have just 90 minutes to diagnose the patient, bring them to the hospital and put in the stent, otherwise there is permanent damage. So problem is, that 1 in 2 heart attacks get initially misdiagnosed at the first point of contact.

Discover the future of medical work with us.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.